Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.30 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2326461 | 1.00 | HSD17B10 (0.35) | HSD17B10MAPTHTTSMN1; SMN2POLB | |
| SCHEMBL9327185 | 0.86 | HTT (0.36) | HSD17B10MAPTHTTSMN1; SMN2POLB | |
| SCHEMBL14003053 | 0.86 | HTT (0.36) | HSD17B10MAPTHTTSMN1; SMN2POLB | |
| SCHEMBL2332745 | 0.86 | CA1 (0.38) | HSD17B10MAPTHTTSMN1; SMN2CXCR2 | |
| SCHEMBL21261493 | 0.86 | CA1 (0.38) | HSD17B10MAPTHTTSMN1; SMN2CXCR2 | |
| SCHEMBL15382587 | 0.86 | CA1 (0.38) | HSD17B10MAPTHTTSMN1; SMN2CXCR2 | |
| SCHEMBL3069494 | 0.83 | SMN1; SMN2 (0.35) | SMN1; SMN2PTGDR2 | |
| SCHEMBL2327079 | 0.83 | SMN1; SMN2 (0.35) | SMN1; SMN2PTGDR2 | |
| SCHEMBL2797629 | 0.83 | SMN1; SMN2 (0.35) | SMN1; SMN2PTGDR2 | |
| SCHEMBL7228766 | 0.83 | AAK1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2978756-B1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CARDIOVASCULAR DISEASES | Bayer Pharma AG (DE) | 2019-03-27 | — | — | EP | disclosed |
| US-10183932-B2 | Substituted oxopyridine derivatives and use thereof cardiovascular disorders | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-01-22 | — | — | US | disclosed |
| EP-2951180-B1 | 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME (US) | 2018-05-02 | — | — | EP | disclosed |
| US-20180086742-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-03-29 | — | — | US | disclosed |
| EP-3063150-B1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | Bayer Pharma AG (DE) | 2017-11-22 | — | — | EP | disclosed |
| US-9822102-B2 | Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-11-21 | — | — | US | disclosed |
| US-9765070-B2 | Substituted oxopyridine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-19 | — | — | US | disclosed |
| US-9540377-B2 | 2,6,7,8 substituted purines as HDM2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20160368903-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-22 | — | — | US | disclosed |
| US-20160272637-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DK) | 2016-09-22 | — | — | US | disclosed |
| US-9434690-B2 | Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-06 | — | — | US | disclosed |
| US-20160052884-A1 | Substituted Oxopyridine Derivatives and Use Thereof in the Treatment of Cardiovascular Disorders | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-02-25 | — | — | US | disclosed |
| EP-2978756-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | Bayer Pharma Aktiengesellschaft (DE) | 2016-02-03 | — | — | EP | disclosed |
| US-20150353553-A1 | 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-12-10 | — | — | US | disclosed |
| EP-2951180-A1 | 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-12-09 | — | — | EP | disclosed |
| WO-2014154794-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014120748-A1 | 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183932-B2 | Substituted oxopyridine derivatives and use thereof cardiovascular disorders | OGFOD1, VASP, PNPO | HSD17B10 2895/4885MAPT 4575/4885HTT 1600/4885 |
| US-20160052884-A1 | Substituted Oxopyridine Derivatives and Use Thereof in the Treatment of Cardiovascular Disorders | OGFOD1, PNPO, VASP | HSD17B10 3135/4885MAPT 4608/4885HTT 1717/4885 |
| US-20180086742-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | OGFOD1, PNPO, VASP | HSD17B10 3135/4885MAPT 4608/4885HTT 1717/4885 |
| US-20160272637-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | OGFOD1, VASP, PNPO | HSD17B10 4073/4885MAPT 4438/4885HTT 1354/4885 |
| US-20160368903-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | OGFOD1, PNPO, VASP | HSD17B10 3135/4885MAPT 4608/4885HTT 1717/4885 |
| US-20150353553-A1 | 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS | DDX21, DPYD, NSUN2 | HSD17B10 3455/4885MAPT 3430/4885HTT 1233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.